Navigation Links
VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
Date:2/28/2011

MOUNTAIN VIEW, Calif., Feb. 28, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its highlights and financial results for the fourth quarter and year ended December 31, 2010.

2010 Highlights

  • In the QNEXA investigational drug development program, we successfully completed the two-year SEQUEL study, an extension study in 675 patients from the CONQUER study.  Results were announced in September and showed sustained weight loss of greater than 10% for both doses of QNEXA over two years.

  • In December, we filed the Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, in the European Union for QNEXA as a treatment for obesity. Obesity is a global epidemic, with approximately 150 million European adults affected and the prevalence is rising rapidly.

  • In the avanafil investigational drug development program, we completed the two remaining phase 3 studies: in diabetics with erectile dysfunction and the long-term open label safety study.  Both studies met all primary efficacy endpoints. The NDA filing for avanafil is scheduled for Q2 2011.

  • We divested MUSE and the related assets to Meda AB for $22 million and are eligible to receive a $1.5 million milestone based upon future sales of MUSE.  The transaction closed on November 5, 2010. In connection with the sale, all of our loans and long-term notes payable were repaid and our MUSE-related royalty obligations were terminated.

  • Lastly, we ended the year with $139.2 million in cash, cash equivalents and available for sale securities.

  • QNEXA Regulatory Update  On October 28, 2010, we received a Complete Response Letter, or CRL, from the FDA regarding the QNEXA NDA.  The FD
    '/>"/>

    SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
    2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
    3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
    4. VIVUS Announces Promotion of Peter Tam to President
    5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
    6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
    7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
    8. VIVUS Announces Sale of MUSE Assets to Meda
    9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
    11. VIVUS to Present at Two Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/2/2015)... March 2, 2015 Cure SMA recently announced a ... Biomedical Research (CALIBR). This funding is an extension of a ... a $700,000 Cure SMA grant to Dr. Peter G. ... "Optimization of Small Molecules that Increase SMN2 Levels ... motor neuron (SMN) protein is critical to the function of ...
    (Date:3/2/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized ... outsourced medical physics services and high quality medical consumable ... the fiscal first quarter 2015 after the market close ... Company will also host a conference call for investors ... Time (10:00 a.m. Eastern Time). Investors may access the ...
    (Date:3/2/2015)... March 2, 2015 Amgen (NASDAQ: ... abstracts, including data evaluating Repatha TM (evolocumab), an ... investigational drug for chronic heart failure, at the upcoming ... Session (ACC.15), being held March 14-16 in ... fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin ...
    Breaking Medicine Technology:Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 4Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 5Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 6Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 7Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 8Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 9Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 10Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 11
    (Date:3/3/2015)... When a lifeguard is on duty, it is important for him ... loose clothing. For a lifeguard, comfort can mean not allowing ... the guard prefers to cover up. Comfort also means staying warm ... the clothing that fits correctly. When a lifeguard is spending ... that the guard stays warm and comfortable throughout the shift. ...
    (Date:3/3/2015)... NY (PRWEB) March 03, 2015 ... high-quality, clinically-based care management programs and a member ... the appointment of Julie O’Brien as President. O’Brien ... Chief Operating Officer. In her new role, she ... for all aspects of AMM’s call center operations, ...
    (Date:3/3/2015)... Dr. Stephen Edgerton, a ... has achieved Accredited Member Status in the American ... this accomplishment after completing a rigorous credentialing process ... the submission of clinical cases for examination. ... up in Connecticut, Charlotte, North Carolina, Caracas, Venezuela ...
    (Date:3/3/2015)... (PRWEB) March 03, 2015 ... research networking-technology corporation, announced today that it has ... the Clinical Data Interchange Standards Consortium (CDISC). HCP ... effort to standardize knowledge-based training and certifications globally. ... IT and web support as well as development ...
    (Date:3/3/2015)... Aliso Viejo, California (PRWEB) March 03, 2015 ... new animated effect entitled inMotion3D Environment from Pixel Film ... turns a 2D HDRI image into 360° viewing area ... Film Studios. “inMotion3D Environment blurs the line between professional ... , Motion 5 users can turn their 2D HDRI ...
    Breaking Medicine News(10 mins):Health News:New Lifeguard Pants Introduced for those Colder Lifeguarding Days 2Health News:New Lifeguard Pants Introduced for those Colder Lifeguarding Days 3Health News:New Lifeguard Pants Introduced for those Colder Lifeguarding Days 4Health News:Julie O'Brien Named President of AliCare Medical Management 2Health News:Julie O'Brien Named President of AliCare Medical Management 3Health News:Dr. Edgerton, a Dentist in Wilmington, NC, Achieves Accredited Status in AACD 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:A New Plugin Entitled inMotion3D Environment Was Released Today from Pixel Film Studios Exclusively for Motion 5 2
    ... Delhi is planning to interlink its major 29 hospitals ... and treatment provided. This computerization and interlinking of data ... by which doctors can know the case history and ... modules of software to deal with different hospital departments. ...
    ... number of psychiatric disorders, including mood disorders, schizophrenia// ... shown to increase the risk for emergence of ... disorder), and that presence of certain anxiety disorders ... development of nicotine dependence. ,A recent study ...
    ... or growing fast: systematic review of size and growth ... who grow rapidly during the first two years of life, ... a study reveals. ,There is an urgent need to ... is not clear how early in life prevention could begin. ...
    ... is no link whatsoever between breast cancer and cholesterol levels ... control the same. ,The details of the study ... Internal Medicine, one of the JAMA/Archives journals. The article says ... to suggest that the statins may work in conjunction with ...
    ... compulsory licensing (CL) provision in the Patents Act that ... Swiss drug maker Roche’s patented drug Tamiflu, useful in ... flu virus. , ,Section 92 empowers the government ... the industry. Furthermore, the issue of such license is ...
    ... a large, heterogeneous group of rare pulmonary disorders ... abnormal gas exchange with considerable mortality and morbidity. ... diagnosis includes more than 100 conditions in both ... and Colorado conducted a descriptive, observational study was ...
    Cached Medicine News:Health News:Delhi Government To Interlink All Major Hospitals Through e-Governance 2Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2Health News:A New Diagnostic Approach To Pediatric Interstitial Lung Disease 2
    ... for Toxoplasmosis has progressed from ... dye test to immunoflourescence, latex ... In addition to Toxo ... both Toxo IgM immunocapture and ...
    ... safe, effective and relatively bloodless procedure for ... easy to learn and can be performed ... outpatient setting with few if any patient ... minimize OR time and use a familiar ...
    ... generally confirmed by a positive heterophil antibody test ... not indicated by the heterophil antibody test. ... percent of children. Detection and identification of ... the stage of EBV infection. Bio-Rad offers ...
    ... can lower healthcare costs with better newborn ... identifying mothers colonized with group B streptococcus ... effective antibiotic prophylaxis. This can prevent illness ... reduce unnecessary antibiotic use in uncolonized women ...
    Medicine Products: